Media Details

  • Home
  • Media
  • Details
  2020-10-28 19:14:03

US FDA approved HWGB’s JV Partner, EBI to conduct Phase IV clinical trial for prevention of COVID-19

KUALA LUMPUR, 28 OCTOBER 2020 – Ho Wah Genting Berhad’s (“HWGB” or the “Company”) (Bursa Stock Code:9601) wholly-owned subsidiary, HWGB Biotech Sdn Bhd’s (“HWGB Biotech”) joint venture partner, US-based E-MO Biology Inc (“EBI”), has obtained approval from the United States Food and Drug Administration (“FDA”) to conduct phase IV clinical trial for a new indication which proposes the use of existing poliomyelitis virus vaccines (“Polio Virus Vaccines”) for prevention of the infectious disease, including vaccines, immunological treatment, diagnostic product development and any similar treatment against the Severe Acute Respiratory Syndrome Coronavirus 2 (“SARS-co-V2”) pandemic and other relevant diseases.

The race to conduct COVID-19 vaccine trials on humans has started in March 2020. Only a few multinational pharmaceutical companies have entered Phase III clinical trial to test the efficacy and side effects of the vaccines developed. 
Phase IV clinical trial (also known as a post-marketing study) is conducted upon FDA approval. The objective is to collect additional information about side-effects and safety, long-term risks and potential benefits, and/or how well the vaccine works when used widely on several thousand people.

It can be used to fast-track a vaccine for emergency use. This is also termed as repurposing vaccines which is very common because many effective vaccines are rediscovered from existing approved vaccines.

As a sponsor of EBI, HWGB Biotech will invest US$1 million and will be entitled to 40% of the total net profit. Furthermore, HWGB Biotech will enjoy exclusive rights for the production, distribution, and sale of the repurposed vaccine based on the polio vaccine for use in preventing COVID-19 infections in Southeast Asia countries.

Chief Executive Officer of HWGB, Dato’ Aaron Lim expressed, “With the FDA approval, we hope the repurposing of the proven poliovirus vaccines can fast track the Covid-19 vaccine development to save lives, as the situation now is dire. Once the clinical trial is proven that the polio vaccines are effective for the prevention of COVID-19, we will start to mass-produce the vaccine to be distributed across South East Asia to help for the dire situation.”

Ho Wah Genting Berhad (“HWGB” or the “Company”) is principally engaged in investment holdings and the provision of management services to its subsidiaries. The Company had on 30 June 2020 diversified its existing businesses to include healthcare-related industry which mainly involved in Health Supplement, Biotechnology, and Health Technology. In addition, the Company and its subsidiaries (“HWGB Group” or the “Group”) are also engaging in the businesses of Investment holdings; manufacturing of wires and cables and molded power supply cord sets and cable assemblies for electrical and electronic devices and equipment; Trading of wires and cables; and travel agent and tour related services.
For more information about HWGB Biotech, follow us on,, Facebook, LinkedIn, and Telegram to view the latest updates about our company ventures in the healthcare industry.

E-Mo Biology Inc (“EBI”) was incorporated in the state of California in the United States of America on 24 May 2020. It is principally involved in conducting biology research and development activities and is the sponsor of a study that indicates the booster polio vaccine to reduce Covid-19 SARS-COV-2 infection and severity.
EBI is founded by Dr. Xie QiYi, who serves as its Managing Director of EBI. He has over 30 years of experience in areas of public health and infection disease control. He was also involved in the development of medical and diagnostic devices, with a focus on Quality, Regulatory and Clinical Affairs for quality systems.